6625-78-1

Basic information

• Product Name: 2-(benzyloxy)propanoic acid
• Synonyms: 2-(benzyloxy)propanoic acid
• CAS NO: 6625-78-1
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180.20048
• Mol File: 6625-78-1.mol
• Article Data: 13

Chemical Properties

• Melting Point: 41-42.5 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 328.2°C at 760 mmHg
• Flash Point: 130.4°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 7.79E-05mmHg at 25°C
• Refractive Index: 1.529
• PKA: 3.57±0.10(Predicted)
• CAS DataBase Reference: 2-(benzyloxy)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)propanoic acid(6625-78-1)
• EPA Substance Registry System: 2-(benzyloxy)propanoic acid(6625-78-1)

Safety Data

• Hazardous Substances Data: 6625-78-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthesis, p. 828, 1978 DOI: 10.1055/s-1978-24902

InChI:InChI=1/C10H12O3/c1-8(10(11)12)13-7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,11,12)

Upstream product

• 2040-44-0 ethyl 2-benzyloxypropionate 
• 849585-22-4 LACTIC ACID 
• 100-39-0 benzyl bromide 
• 598-78-7 (R,S)-2-chloropropionic acid 
• 100-51-6 benzyl alcohol 
• 74-83-9 methyl bromide 
• 30379-55-6 benzyloxyacetic acid 
• 598-72-1 2-Bromopropionic acid 
• 20194-18-7 sodium phenyl-methanolate 
• 485-71-2 Cinchonidin 
• 53346-03-5 2-benzyloxypropionic acid methyl ester 
• 100-44-7 benzyl chloride 
• 81927-55-1 O-benzyl 2,2,2-trichloroacetimidate 
• 74-88-4 methyl iodide 

Downstream Products

• 170985-85-0 N’-[(1S,2S)-2-(benzyloxy)-1-ethylpropyl]formic hydrazide 
• 184177-83-1 2-[(1S,2S)-1-ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-3H-1,2,4-triazol-3-one 
• 170985-86-1 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-1H-1,2,4-triazol-5(4H)-one 
• 77287-11-7 methyl (S)-2-(benzyloxy)propanoate 
• 81445-44-5 (S)-2-(benzyloxy)propanal 
• 170985-84-9 (S)-N'-(2-(benzyloxy)propylidene)formylhydrazide 
• 100836-85-9 (R)-2-benzyloxypropionic acid 
• 33106-32-0 (S)-2-(benzyloxy)propanoic acid 
• 1146218-81-6 ((1-methoxyethoxy)methyl)benzene 
• 140-11-4 Benzyl acetate 
• 34097-57-9 (±)-2-(benzyloxy)propanenitrile 

Relevant articles and documents

COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS

The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.

Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof

A process for the preparation of 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one compound of formula-1, its intermediates and polymorphs thereof. (I)

Microbial deracemization of α-substituted carboxylic acids: Substrate specificity and mechanistic investigation

A new enzymatic method for the preparation of optically active α-substituted carboxylic acids is reported. This technique is called deracemization reaction, which provides us with a route to obtain the enantiomerically pure compounds, theoretically in 100% yield starting from the racemic mixture. This means that the synthesis of a racemate is almost equal to the synthesis of the optically active compound, and this concept is entirely different from the commonly accepted one in the asymmetric synthesis. Using the growing cell system of Nocardia diaphanozonaria JCM3208, racemates of 2-aryl- and 2-aryloxypropanoic acid are deracemized smoothly and (R)-form-enriched products are recovered in high chemical yield (>50%). In addition, using optically active starting compounds and deuterated derivatives as well as inhibitors, we have disclosed the fact that a new type of enzyme takes part in this biotransformation, and that the reaction proceeds probably via the same mechanism as that in rat liver.